Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-led-research-confirms-novel-targeted-therapy-doubles-the-effectiveness-of-current-standard-treatment-for-alk-positive-lung-cancer
https://www.med.cuhk.edu.hk/press-releases/cuhk-led-research-confirms-novel-targeted-therapy-doubles-the-effectiveness-of-current-standard-treatment-for-alk-positive-lung-cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

An international research led by The Chinese University of Hong Kong (CUHK) has confirmed a novel targeted therapy which is twice as effective as the current standard treatment for ALK-positive lung cancer because it doubles the progression-free survival time, and at the same time, lowers the chance of brain metastases.  ALK is a gene that produces a protein that helps cancer cells grow and spread, according to the American Cancer Society (ACS).

 

This global study, led by Prof. Tony MOK, will set the new standard of care for initial treatment for ALK-positive lung cancer patients throughout the world.  The findings of this study were just published in the leading international medical journal The New England Journal of Medicine on 7 June 2017, and presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting on the same day.  

 

‘Alectinib’ halts lung cancer growth for 15 months longer than current standard therapy

Lung cancer is the most common cancer in the world, accounting for 1.6 million deaths every year. It is also the leading cause of cancer deaths in Hong Kong, with over 4,000 new cases every year.  Of these, 80% suffer from non-small-cell lung cancer (NSCLC) and about 5% of these cases are ALK-positive.  ‘Crizotinib’ is the current standard of care, while Alectinib (a second generation ALK inhibitor) is approved for usage upon crizotinib failure.  Alectinib is a more potent, next generation inhibitor of ALK and this is the first global study to compare the two targeted therapies.

 

Prof. Tony Shu Kam MOK, Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology of the Faculty of Medicine of CUHK, explained, ‘Although the majority of patients respond well to Crizotinib initially, the cancer typically starts growing again within 12 months.  Also, like many drugs available for lung cancer treatment, Crizotinib is not effective against brain metastases due to the presence of the blood-brain barrier which prevents toxins (including chemotherapy and targeted therapies) from entering the brain.’

 

Prof. Tony MOK led a multinational study from 2014 to 2016 on 303 patients from 29 countries with ALK-positive NSCLC.  Previously untreated, all patients were randomly divided into two groups; one group to receive Alectinib and the other Crizotinib over the same period.

 

Results revealed that Alectinib recorded a median of more than 25.7 months of progression-free survival, over double that of Crizotinib (10.4 months).  In addition, the probability of 1-year event-free survival was close to 70% with Alectinib, as opposed to 50% with Crizotinib.  It also had fewer side effects and was associated with greater reduction in lung cancer symptoms and greater improvement in quality of life.

 

The results are summarized in the table below:

 

 Alectinib (152 patients)Crizotinib (151 patients)
Progression-free survival (Median)25.7 months10.4 months
12-month event-free survival rate68%49%
Central Nervous System Progression12%45%

 

New therapy especially beneficial in controlling and lowering the chance of brain metastases

The research team also proved that the novel targeted therapy was 70% more effective than the current standard of care in preventing tumours from spreading to the brain as it penetrates better into the brain and kills cancer cells.   

 

Professor MOK described the research findings as very significant and encouraging, ‘The study has proved that the second-line therapy outperforms the current standard one in  first-line treatment for ALK-positive lung cancer, meaning that the first-line use of Alectinib will be a new standard of care for these patients, with the belief that they can live longer and better.’

 

This remarkable research result by Professor MOK makes another important breakthrough in lung cancer treatment after his findings in 2014 proved that molecular targeted therapy is superior to standard first-line chemotherapy in ALK-positive lung cancer patients.  His  landmark study in 2009 also established the role of first-line treatment in patients with EGFR mutation, later suggesting a new treatment paradigm in 2016.  By understanding the molecular profile of lung cancer, physicians can customize the treatment for patients according to the genetic information of their tumor. This brings personalized medicine development of lung cancer into a new stage and enhances patients’ quality of life.

 

A multinational study led by Prof. Tony Shu Kam MOK, Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology of the Faculty of Medicine of CUHK (left), has confirmed a novel targeted therapy can extend the progression-free survival time (median) more than a double compared to the current standard treatment for advanced ALK-positive lung cancer patients, and at the same time, lower the chance of brain metastases. Also featured in the picture are ALK-positive lung cancer patient Madam TAM (centre) and Dr LAM Kwok Chi, Clinical Assistant Professor (Honorary), Department of Clinical Oncology, Faculty of Medicine at CUHK (right).

A multinational study led by Prof. Tony Shu Kam MOK, Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology of the Faculty of Medicine of CUHK (left), has confirmed a novel targeted therapy can extend the progression-free survival time (median) more than a double compared to the current standard treatment for advanced ALK-positive lung cancer patients, and at the same time, lower the chance of brain metastases. Also featured in the picture are ALK-positive lung cancer patient Madam TAM (centre) and Dr LAM Kwok Chi, Clinical Assistant Professor (Honorary), Department of Clinical Oncology, Faculty of Medicine at CUHK (right).

Prof. Tony MOK says that the study has proved that the second-line therapy outperforms the current standard one in first-line treatment for ALK-positive lung cancer, meaning that the first-line use of Alectinib will be a new standard of care for these patients, with the belief that they can live longer and better.

Prof. Tony MOK says that the study has proved that the second-line therapy outperforms the current standard one in first-line treatment for ALK-positive lung cancer, meaning that the first-line use of Alectinib will be a new standard of care for these patients, with the belief that they can live longer and better.

More Press Releases

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

Research
International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
 CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

Research
CUHK co-leads global lung cancer study  Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

CUHK co-leads global lung cancer study Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

Research
CU Medicine collaborates with South Korean institutes to develop  an AI-powered analytic tool for lung cancer immunotherapy

CU Medicine collaborates with South Korean institutes to develop an AI-powered analytic tool for lung cancer immunotherapy

Research
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium
CU Medicine developed an innovative mRNA drug for treatment of nasopharyngeal carcinoma

CU Medicine developed an innovative mRNA drug for treatment of nasopharyngeal carcinoma

Research
CU Medicine combats resistance to immunotherapy in liver cancer

CU Medicine combats resistance to immunotherapy in liver cancer

Research
CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment

CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment

Research
CUHK discovers a blood regulator linked to tumour microenvironment formation,  sparking a new therapeutic target for lung cancer

CUHK discovers a blood regulator linked to tumour microenvironment formation, sparking a new therapeutic target for lung cancer

Research
CUHK study finds rising laryngeal cancer rates among women in some locations, despite global decline

CUHK study finds rising laryngeal cancer rates among women in some locations, despite global decline

Research
Professor Anthony Chan honoured with the ESMO Lifetime Achievement Award  Global recognition for his leadership and outstanding research in nasopharyngeal cancer

Professor Anthony Chan honoured with the ESMO Lifetime Achievement Award Global recognition for his leadership and outstanding research in nasopharyngeal cancer

Awards and honors
CUHK Phase 1 Clinical Trial Centre celebrates 10th anniversary Centre has completed 150 early-stage studies of novel drugs for cancer, diabetes and more

CUHK Phase 1 Clinical Trial Centre celebrates 10th anniversary Centre has completed 150 early-stage studies of novel drugs for cancer, diabetes and more

Research
CU Medicine’s Assisted Reproductive Technology (ART) Unit preserves the reproductive ability of cancer patients in Hong Kong

CU Medicine’s Assisted Reproductive Technology (ART) Unit preserves the reproductive ability of cancer patients in Hong Kong

Research
CUHK study concludes that plasma EBV DNA screening can detect early asymptomatic nasopharyngeal cancer and reflect the risk of future cancer development

CUHK study concludes that plasma EBV DNA screening can detect early asymptomatic nasopharyngeal cancer and reflect the risk of future cancer development

Research
CUHK’s study sees small intestinal cancer incidence rising globally and in Hong Kong Higher incidence observed in high-income countries

CUHK’s study sees small intestinal cancer incidence rising globally and in Hong Kong Higher incidence observed in high-income countries

Research
CUHK performs world’s first robotic-assisted bronchoscopic  microwave ablation of lung metastases

CUHK performs world’s first robotic-assisted bronchoscopic microwave ablation of lung metastases

Surgical advancement
CUHK study sees a rising trend in primary brain cancer incidence in younger males in high-income countries

CUHK study sees a rising trend in primary brain cancer incidence in younger males in high-income countries

Research
CUHK unlocks the secret of cancer pain  Identifying a new therapeutic key to ending the sorrow

CUHK unlocks the secret of cancer pain Identifying a new therapeutic key to ending the sorrow

Research
CUHK first discovers obese patients with diabetes and fluctuating blood glucose control had a high cancer risk while patients with diabetes treated with a common class of blood pressure lowering drug had a low cancer risk

CUHK first discovers obese patients with diabetes and fluctuating blood glucose control had a high cancer risk while patients with diabetes treated with a common class of blood pressure lowering drug had a low cancer risk

Research
CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial

CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial

Research
CUHK’s study sees a rising trend of multiple myeloma incidence,  particularly in older males from high-income countries

CUHK’s study sees a rising trend of multiple myeloma incidence, particularly in older males from high-income countries

Research
CUHK finds the largest rise in incidence of Hodgkin lymphoma in Asia Rising trend of male incidence means Hong Kong tops the world

CUHK finds the largest rise in incidence of Hodgkin lymphoma in Asia Rising trend of male incidence means Hong Kong tops the world

Research
CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

Surgical advancement
CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

Research
CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

Research
CUHK Study Finds Half of Childhood Cancer Survivors Used Complementary and Alternative Medicine

CUHK Study Finds Half of Childhood Cancer Survivors Used Complementary and Alternative Medicine

Research
Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

Research
CUHK Study Finds Earlier Endoscopy Did Not Reduce Mortality and Risk of Further Bleeding in Acute Upper Gastrointestinal Bleeding Patients

CUHK Study Finds Earlier Endoscopy Did Not Reduce Mortality and Risk of Further Bleeding in Acute Upper Gastrointestinal Bleeding Patients

Research
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors
CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

Research
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
CUHK Jointly Discovers New Therapeutic Solution for Minor Stroke in Global Study with over 30 Countries

CUHK Jointly Discovers New Therapeutic Solution for Minor Stroke in Global Study with over 30 Countries

Research
CUHK Sees Early Evaluation of TIA Patients Reduce Rate of Stroke by 70% in a Global Study of 21 Countries

CUHK Sees Early Evaluation of TIA Patients Reduce Rate of Stroke by 70% in a Global Study of 21 Countries

Research
The 7th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care in the Community’

The 7th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care in the Community’

Symposium
Factsheet on Personalised Medicine (Only available in Chinese Version)

Factsheet on Personalised Medicine (Only available in Chinese Version)

Research
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research
CUHK and HKU Host the 5th Annual Palliative Care Symposium for Health Care Workers in Chinese Population

CUHK and HKU Host the 5th Annual Palliative Care Symposium for Health Care Workers in Chinese Population

Symposium
CUHK Pioneers Innovative Computer Assisted Tumor Surgery for Bone Cancer Patients

CUHK Pioneers Innovative Computer Assisted Tumor Surgery for Bone Cancer Patients

Surgical advancement
Bowel Cancer Will Become Top Cancer in Hong Kong CUHK Introduces Colon Pill Camera to Prevent Bowel Cancer

Bowel Cancer Will Become Top Cancer in Hong Kong CUHK Introduces Colon Pill Camera to Prevent Bowel Cancer

Surgical advancement
CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

Clinical service
The Chinese University of Hong Kong Nethersole School of Nursing hosts the Fifth Pan-Pacific Nursing Conference and Seventh Nursing Symposium on Cancer Care

The Chinese University of Hong Kong Nethersole School of Nursing hosts the Fifth Pan-Pacific Nursing Conference and Seventh Nursing Symposium on Cancer Care

Symposium
Predicting Your Colorectal-polyp Risk with CUHK Colorectal-polyp Prediction Index (CU-CPI)

Predicting Your Colorectal-polyp Risk with CUHK Colorectal-polyp Prediction Index (CU-CPI)

Clinical service

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.